Over the past 3 months, 7 analysts have published their opinion on Beauty Health (NASDAQ:SKIN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.
Trending: ‘You’re Blowing This:’ Donald Trump’s Wife Melania Was Convinced He Was ‘Screwing Up,’ New Book Says
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
According to 7 analyst offering 12-month price targets in the last 3 months, Beauty Health has an average price target of $23.14 with a high of $30.00 and a low of $20.00.
Below is a summary of how these 7 analysts rated Beauty Health over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
© Provided by Benzinga price target chart
This current average is unchanged from the previous average price target.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company’s revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Latest Ratings for SKIN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | JP Morgan | Initiates Coverage On | Overweight | |
| Feb 2022 | DA Davidson | Maintains | Buy | |
| Jan 2022 | William Blair | Initiates Coverage On | Outperform |
View More Analyst Ratings for SKIN
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
